OrbiMed’s C4 Therapeutics CCCC Stock Holding History

OrbiMed’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-150,000	Closed	-$540K	–	112
2024 Q4	$540K	Hold	150,000	–	–	0.01%	114
2024 Q3	$855K	Buy	+150,000	New	+$903K	0.02%	116

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

OrbiMed's CCCC Position: Q2 2026 in Review

OrbiMed sold out of C4 Therapeutics (CCCC) in Q2 2026, closing a stake of 856,353 shares — an estimated $2.25M sold.

OrbiMed first reported a position in CCCC in Q2 2024 and held it in 8 quarters. The position peaked at $25M in Q3 2024. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

OrbiMed reported no remaining C4 Therapeutics position as of Q2 2026 after selling out during the quarter.
OrbiMed sold 856,353 C4 Therapeutics shares in Q2 2026, an estimated $2.25M.
OrbiMed first reported a position in C4 Therapeutics in Q2 2024 and held it in 8 quarters.
OrbiMed's C4 Therapeutics position peaked at $25M in Q3 2024.
148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.